Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Receivables (2016 - 2025)

Veracyte (VCYT) has disclosed Receivables for 14 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 4.01% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.7 million through Dec 2025, down 4.01% year-over-year, with the annual reading at $44.7 million for FY2025, 4.01% down from the prior year.
  • Receivables hit $44.7 million in Q4 2025 for Veracyte, down from $47.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $53.8 million in Q1 2025 to a low of $27.9 million in Q1 2021.
  • Historically, Receivables has averaged $43.3 million across 5 years, with a median of $43.3 million in 2022.
  • Biggest five-year swings in Receivables: skyrocketed 7961.8% in 2021 and later fell 8.28% in 2023.
  • Year by year, Receivables stood at $41.5 million in 2021, then rose by 6.17% to $44.0 million in 2022, then fell by 8.28% to $40.4 million in 2023, then increased by 15.22% to $46.5 million in 2024, then decreased by 4.01% to $44.7 million in 2025.
  • Business Quant data shows Receivables for VCYT at $44.7 million in Q4 2025, $47.8 million in Q3 2025, and $50.8 million in Q2 2025.